Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab with either palbociclib plus letrozole or paclitaxel for postmenopausal women with estrogen receptor-positive/HER2-positive breast cancer - The TOUCH trial

被引：0
|
作者：
Biganzoli, Laura
Brain, Etienne
Malorni, Luca
Gombos, Andrea
Hasler-Strub, Ursula
Zamagni, Claudio
Chakiba, Camille
Roschitzki-Voser, Heidi
Regan, Meredith M.
机构：
[1] Int Breast Canc Study Grp, Bern, Switzerland
[2] TOUCH Investigators, Bern, Switzerland
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT-28-02
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II randomized trial of neoadjuvant trastuzumab and pertuzumab (TP) with either palbociclib plus letrozole (Pal plus L) or paclitaxel (Pac) for elderly patients with estrogen receptor & HER2 positive (ER+/HER2+) breast cancer (BC) (International Breast Cancer Study Group IBCSG 55-17, TOUCH)
    Biganzoli, L.
    Brain, E.
    Malorni, L.
    Risi, E.
    Regan, M. M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Jisun Kim
    Woosung Lim
    Eun-Kyu Kim
    Min-Kyoon Kim
    Nam-Sun Paik
    Sang-Seol Jeong
    Jung-han Yoon
    Chan Heun Park
    Sei Hyun Ahn
    Lee Su Kim
    Sehwan Han
    Seok Jin Nam
    Han-Sung Kang
    Seung Il Kim
    Young Bum Yoo
    Joon Jeong
    Tae Hyun Kim
    Taewoo Kang
    Sung-Won Kim
    Yongsik Jung
    Jeong Eon Lee
    Ku Sang Kim
    Jong-Han Yu
    Byung Joo Chae
    So-Youn Jung
    Eunyoung Kang
    Su Yun Choi
    Hyeong-Gon Moon
    Dong-Young Noh
    Wonshik Han
    BMC Cancer, 14
  • [3] Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR)
    Kim, Jisun
    Lim, Woosung
    Kim, Eun-Kyu
    Kim, Min-Kyoon
    Paik, Nam-Sun
    Jeong, Sang-Seol
    Yoon, Jung-han
    Park, Chan Heun
    Ahn, Sei Hyun
    Kim, Lee Su
    Han, Sehwan
    Nam, Seok Jin
    Kang, Han-Sung
    Kim, Seung Il
    Yoo, Young Bum
    Jeong, Joon
    Kim, Tae Hyun
    Kang, Taewoo
    Kim, Sung-Won
    Jung, Yongsik
    Lee, Jeong Eon
    Kim, Ku Sang
    Yu, Jong-Han
    Chae, Byung Joo
    Jung, So-Youn
    Kang, Eunyoung
    Choi, Su Yun
    Moon, Hyeong-Gon
    Noh, Dong-Young
    Han, Wonshik
    BMC CANCER, 2014, 14
  • [4] Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
    Johnston, Stephen
    Puhalla, Shannon
    Wheatley, Duncan
    Ring, Alistair
    Barry, Peter
    Holcombe, Chris
    Boileau, Jean Francois
    Provencher, Louise
    Robidoux, Andre
    Rimawi, Mothaffar
    McIntosh, Stuart A.
    Shalaby, Ibrahim
    Stein, Robert C.
    Thirlwell, Michael
    Dolling, David
    Morden, James
    Snowdon, Claire
    Perry, Sophie
    Cornman, Chester
    Batten, Leona M.
    Jeffs, Lisa K.
    Dodson, Andrew
    Martins, Vera
    Modi, Arjun
    Osborne, C. Kent
    Pogue-Geile, Katherine L.
    Cheang, Maggie Chon U.
    Wolmark, Norman
    Julian, Thomas B.
    Fisher, Kate
    MacKenzie, Mairead
    Wilcox, Maggie
    Bartlett, Cynthia Huang
    Koehler, Maria
    Dowsett, Mitch
    Bliss, Judith M.
    Jacobs, Samuel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (03) : 178 - +
  • [5] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer
    Cascetta, Krystal P.
    Poulikakos, Poulikos
    Shapiro, Charles
    Fasano, Julie
    Bhardwaj, Aarti
    Irie, Hanna
    Goel, Anupama
    Klein, Paula
    Adams, Sylvia
    Kalinsky, Kevin
    Vahdat, Linda
    Ru, Meng
    Tiersten, Amy
    CANCER RESEARCH, 2018, 78 (04)
  • [6] A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE)
    Patel, Rima
    Cascetta, Krystal
    Klein, Paula
    Moshier, Erin
    Kwa, Maryann
    Fasano, Julie
    Goel, Anupama
    Accordino, Melissa
    Shapiro, Charles
    Vaccaro, Rita
    Joshi, Gargi Atul
    Sparano, Joseph
    Tiersten, Amy
    CANCER RESEARCH, 2024, 84 (09)
  • [7] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer
    Jinno, H.
    Sato, T.
    Takahashi, M.
    Hayashida, T.
    Sakata, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab and pertuzumab in HR-positive, Her2-positive metastatic breast cancer.
    Cascetta, Krystal Pauline
    Poulikakos, Poulikos
    Shapiro, Charles L.
    Bhardwaj, Aarti Sonia
    Fasano, Julie
    Irie, Hanna
    Klein, Paula
    Goel, Anupama
    Kalinsky, Kevin
    Adams, Sylvia
    Andreopoulou, Eleni
    Jaffer, Shabnam
    Ru, Meng
    Tiersten, Amy
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] A phase II neoadjuvant trial of concurrent trastuzumab and paclitaxel without anthracycline in women with HER2-positive operable breast cancer.
    Jinno, H.
    Hayashida, T.
    Takahashi, M.
    Hirose, S.
    Kitagawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [10] Phase II neoadjuvant trial of Interferon-gamma plus weekly paclitaxel, trastuzumab and pertuzumab in patients with HER-2 positive breast cancer
    Han, Hyo S.
    Costa, Ricardo
    Armaghani, Avan
    Soyano, Aixa
    Loftus, Loretta
    Soliman, Hatem
    Fridley, Brooke
    Whiting, Junmin
    Cerezo, Aiana
    Rosa, Marilin
    Extermann, Martine
    Khong, Hung
    Czerniecki, Brian
    CANCER RESEARCH, 2022, 82 (04)
12345